Blaupause für Medikamentenmanagement mit Zusatznutzen

Abstract

What connects the selective contractual care offer eLiSa (1) of AOK Nordost and the innovation fund projects AdAM (2), TOP (3), eRIKA (4) of BARMER and AOK Nordost with the DMP requirements guideline for requirements for structured treatment programmes for patients with type 1 diabetes mellitus and the medication management including medication plan planned with the ePA (5) from 2025? The problem with the latter two: It is not defined how medication management and the medication plan should be implemented. Both the G-BA in its DMP-A guideline (6) and the legislator in the definition of the medication plan (7) leave this completely open. Although the legislator stipulates that dosage and intake instructions should be ‚clearly and comprehensibly documented‘, nothing more than documentation has been specified to date. The situation is different with the AOK Nordost ‚electronic Life Saver‘ (eLiSa for short) and BARMER‘s ‚AdAM‘, which were jointly awarded the first prize for patient safety by the Patient Safety Action Alliance and the first prize of the MSD Health Prize 2023, and the expansion stage planned this year can certainly be regarded as a blueprint for medication management, especially for DMPs and ePAs.